Mariner
VIVO

Mariner’s Meridian Bioscience Inc VIVO Stock Holding History

Mariner’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-24,795
Closed -$823K – 2934
2022
Q4 		$823K Buy
24,795
+122
+0.5% +$3.93K ﹤0.01% 1332
2022
Q3 		$778K Sell
24,673
-70
-0.3% -$2.27K ﹤0.01% 1172
2022
Q2 		$752K Buy
24,743
+563
+2% +$15.2K ﹤0.01% 1009
2022
Q1 		$628K Buy
24,180
+11,597
+92% +$276K ﹤0.01% 1064
2021
Q4 		$257K Sell
12,583
-1,607
-11% -$30.8K ﹤0.01% 1123
2021
Q3 		$273K Sell
14,190
-501
-3% -$9.99K ﹤0.01% 951
2021
Q2 		$326K Buy
14,691
+413
+3% +$8.76K ﹤0.01% 860
2021
Q1 		$375K Sell
14,278
-817
-5% -$19.4K ﹤0.01% 783
2020
Q4 		$282K Buy
15,095
+2,231
+17% +$41.7K ﹤0.01% 758
2020
Q3 		$218K Hold
12,864
– – ﹤0.01% 706
2020
Q2 		$300K Buy
+12,864
New +$186K ﹤0.01% 677
2019
Q1 		– Sell
-34,051
Closed -$591K – 1063
2018
Q4 		$591K Buy
+34,051
New +$581K 0.01% 540
2015
Q4 		– Sell
-22,000
Closed -$376K – 569
2015
Q3 		$376K Buy
22,000
+2,875
+15% +$52.5K 0.02% 367
2015
Q2 		$356K Buy
+19,125
New +$355K 0.02% 396

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Mariner's VIVO Position: Q1 2023 in Review

Mariner sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 24,795 shares — an estimated $823K sold.

Mariner first reported a position in VIVO in Q2 2015 and held it in 14 quarters. The position peaked at $823K in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Mariner reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Mariner sold 24,795 Meridian Bioscience Inc shares in Q1 2023, an estimated $823K.
  • Mariner first reported a position in Meridian Bioscience Inc in Q2 2015 and held it in 14 quarters.
  • Mariner's Meridian Bioscience Inc position peaked at $823K in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Mariner's 13F filing for Q1 2023, filed 15 May 2023.